The aim of this study was to identify the effect of glycine on insulin secretion and action in healthy first-degree relatives of Type 2 diabetes mellitus patients. A randomized, double-blind, placebo-controlled clinical trial was performed in 12 healthy, non-obese volunteers who were first-degree relatives of Type 2 diabetes mellitus patients. Six volunteers received a morning dose of glycine 5 g orally and the other six received placebo. At baseline without drugs and after pharmacological intervention, a metabolic profile and, to assess insulin secretion and action, a hyperglycemic-hyperinsulinemic clamp study were performed. There were no significant differences in baseline metabolic profile, insulin secretion or action between groups. Changes from baseline of early (p < 0.05), late (p < 0.05), and total insulin (p < 0.02) responses were higher in the glycine group than in controls. There were no significant differences in the changes from baseline of insulin action between groups. In conclusion, a morning dose of glycine 5 g orally increased early, late and total insulin responses without changes in insulin action in healthy first-degree relatives of Type 2 diabetes mellitus patients.
Key words:
Amino Acid - Insulin Secretion - Insulin Sensitivity - Family History of Type 2 Diabetes Mellitus - Glycine
References
-
1 Cook D L, Taborsky G J. ß-cell function and insulin secretion. In: Porte D, Sherwin RS (eds). Diabetes Mellitus, 5th ed. Connecticut:; Appleton & Lange, 1997: 49-73
-
2 Groff J L, Gropper S S. Advanced nutrition and human metabolism, 3rd ed. Belmont, Ca, USA:; Wadsworth/Thomson Learning, 1999: 163-244
-
3
Perseguin G, Ghosh S, Gerow K, Shulman G I.
Metabolic defects in lean nondiabetic offspring of NIDDM parents. A cross-sectional study.
Diabetes.
1997;
46
1001-1009
-
4
DeFronzo R A, Tobin J D, Andres R.
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
Am J Physiol.
1979;
237
E214-E223
-
5
Fujimoto W Y.
The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus.
Am J Med.
2000;
108 (Suppl 6A)
9S-14S
-
6
Porte D, Jr.
Banting lecture 1990. Beta-cells in type II diabetes mellitus.
Diabetes.
1991;
40
166-180
-
7
Hu S, Wang S, Fanelli B, Bell P A, Dunning B E, Geisse S, Schmitz R, Boettcher B R.
Pancreatic beta-cell K (ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
J Pharmacol Exp Ther.
2000;
293
444-452
-
8
Wollheim C B.
Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes.
Diabetologia.
2000;
43
265-277
-
9
Roberge J N, Brubaker P L.
Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
Endocrinology.
1993;
133
233-240
-
10
Thorens B.
Glucagon-like peptide-1 and control of insulin secretion.
Diabete Metab.
1995;
21
311-318
-
11
Chausmer A B.
Zinc, insulin and diabetes.
J Am Coll Nutr.
1998;
17
109-115
-
12
Bray G A.
Afferent signals regulating food intake.
Proc Nutr Soc.
2000;
59
373-384
-
13
Traxinger R R, Marshall S.
Role of amino acids in modulating glucose-induced desensitization of the glucose transport system.
J Biol Chem.
1989;
264
20 910-20 916
M. González-Ortiz,M.D., M.Sc., Ph.D.
Montes Urales 1409
Colonia Independencia
44340, Guadalajara
México
Phone: Phone:+ 52 (3) 826-7022
Fax: Fax:+ 52 (3) 616-1218
Email: E-mail:uiec@prodigy.net.mx
